Serán Bioscience Revenue and Competitors

Bend, OR USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Serán Bioscience's estimated annual revenue is currently $35.8M per year.(i)
  • Serán Bioscience's estimated revenue per employee is $193,750

Employee Data

  • Serán Bioscience has 185 Employees.(i)
  • Serán Bioscience grew their employee count by 38% last year.

Serán Bioscience's People

NameTitleEmail/Phone
1
Director OperationsReveal Email/Phone
2
Operations Specialist IIReveal Email/Phone
3
President, CEO and FounderReveal Email/Phone
4
Manufacturing EngineerReveal Email/Phone
5
Marketing CoordinatorReveal Email/Phone
6
Facilities TechnicianReveal Email/Phone
7
GMP Manufacturing CoordinatorReveal Email/Phone
8
Quality Associate IIIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-54%N/AN/A
#2
$18.8M12111%N/AN/A
#3
$6.8M447%N/AN/A
#4
$0.8M50%N/AN/A
#5
$35.8M18538%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$2.6M170%N/AN/A
#8
$0.8M50%N/AN/A
#9
$8.1M524%N/AN/A
#10
$0.8M50%N/AN/A
Add Company

What Is Serán Bioscience?

Our mission is to provide optimized drug development and manufacturing services for our clients, from Discovery to the Clinic. Our science-driven approach utilizes predictive design tools, novel chemistry, analytical tools, enabling delivery technologies, and a thorough knowledge of quality and regulatory requirements. We are experts in delivery of poorly soluble compounds using a variety of technologies including spray drying, nano-particulates, micronization, lipid vehicles, and salt forms Our custom-built spray driers enable a wide variety of particle formation, from nano-structures to micro-particulates Our particle engineering approaches are combined with our broad expertise in solid dosage forms resulting in the optimum clinical trial materials for your drug, from suspensions to capsules to tablets

keywords:N/A

N/A

Total Funding

185

Number of Employees

$35.8M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Serán Bioscience News

2022-04-17 - Rapid evolution of SARS-CoV-2 challenges human defenses ...

Indeed, recent reports indicate that the convalescent sera and BNT162b2 ... through research made available to the Computational BioScience.

2022-04-13 - Co-treatment with Esculin and erythropoietin protects against ...

Results are expressed as mean ± SD (n = 8), *p < 0.05, **p < 0.01, ***p < 0.001, ... then sera were separated and stored at ? 80 °C for the...

2022-04-06 - Antigenicity comparison of SARS?CoV?2 Omicron ...

While the D614G virus escaped the Omicron spike-immunized sera, ... mAb 9MW33 was from Mabwell Bioscience Co.; mAb 604 was from Prof.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M192N/AN/A
#2
$52.2M1936%N/A
#3
$58.8M1986%N/A
#4
$65.9M22221%N/A
#5
$70.8M2227%N/A